AACR 2024: Analytical validation of a complete system for detection and characterization of genomic aberrations in circulating tumor DNA

Frontage Laboratories has validated a liquid biopsy NGS assay supporting Gradalis Inc.’s Vigil® vaccine. Our cfDNA platform targets 293 oncology genes using automated extraction, high-depth sequencing (~4,000×), and barcode-based bioinformatics to accurately detect low-frequency variants. This enables precise tumor profiling, vaccine monitoring, and supports patient selection for personalized immunotherapy.

"*" indicates required fields

First Name*

Last Name*

Company*

State*